Skip to content
Review Open access

Vagus nerve stimulation neuromodulation for refractory epilepsy: a systematic review and network meta-analysis of randomized controlled trials

Oct 2026 · ANPAbstract_CBN26 · 0 citations

Abstract

Background: Refractory epilepsy is a condition that requires multimodal and specialized clinical management. In this context, neuromodulation therapies have emerged in recent years, notably two different approaches involving the same nerve structure: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) and Invasive Vagus Nerve Stimulation (iVNS). Objective: To review the effectiveness of the two primary forms of Vagus Nerve stimulation in the treatment of refractory epilepsy. Methods: A network meta-analysis conducted according to PRISMA 2020 guidelines. The PICO strategy guided the search in PubMed/MEDLINE, Embase, and Cochrane Library in February 2026, without language or date restrictions. Randomized Controlled Trials (RCTs) involving patients diagnosed with drug-resistant epilepsy treated with iVNS or taVNS versus sham control were included. Statistical analysis was performed using R software (5.4.2). The dichotomous outcome evaluated was the responder rate (reduction in at least 50% of seizures), using Risk Ratio (RR) as the effect measure, analyzed via the Mantel-Haenszel (M-H) method in a random-effects model (DerSimonian-Laird). Heterogeneity was measured by tau and I² (Cochran's Q). P-Scores were calculated to rank therapies in the network model. Risk of bias was assessed using the RoB 2.0 tool. Results: Six RCTs were included (3 comparing taVNS vs. Sham; 3 comparing iVNS vs. Sham), totaling 622 patients. A significant difference was found favoring taVNS over Sham (RR=1.58; 95% CI [1.04; 2.40]; p=0.031) regarding responder rates, which was not observed for iVNS vs. Sham (RR=1.51; 95% CI [0.94; 2.42]; p=0.089). Overall heterogeneity was low (I² = 10.2%; tau = 0.13). No significant difference was found in the network comparison between iVNS and taVNS (RR=0.96; 95% CI [0.51; 1.80]). P-Scores ranked taVNS as the superior treatment (0.7704), followed by iVNS (0.6993) and Sham (0.0303). Regarding the overall risk of bias: 1 study was "low risk," 3 had "some concerns," and 2 were "high risk”. Conclusion: Both taVNS and iVNS show promising results in managing refractory epilepsy. However, the limited number of RCTs and the lack of direct head-to-head comparisons are significant limitations. Larger, methodologically robust RCTs are necessary for more definitive conclusions.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.